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Abstract
Autologous adipose stromal vascular fractions (SVFs) containing adipose tissue-derived stem cells (ASCs) are
currently being used in clinical settings for various orthopedic applications for human patients. Due to its
potential capability of regenerating cartilage, bone, and tendons, autologous adipose SVFs are being tried
in treating patients with osteoarthritis (OA), chondromalacia, meniscus tear, osteonecrosis of the femoral
head, and tendon injuries. Here, we have reviewed available human clinical studies with regard to patient applications
of autologous adipose SVF containing ASCs, specifically assessing effectiveness and safety in the field of orthopedic
disorders. All studies reviewed in this article presents potential benefits of autologous adipose SVF in various orthopedic
applications without any serious side effects.
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Background
Musculoskeletal injuries and damage are common health
problems in both young and old patients [1]. Various
treatment modalities are available for such musculoskel-
etal injuries. However, most of these modalities provide
only symptomatic relief [2]. The regenerative potential
of injured and damaged tissue with stem cells is a prom-
ising new treatment strategy in the field of orthopedics.
Stem cells can be categorized into two major forms:
embryonic stem cells and adult stem cells [3]. Adult
stem cells, which include mesenchymal stem cells
(MSCs), can be further divided into non-culture ex-
panded forms, also known as stromal vascular fractions
(SVF), and culture expanded forms [3]. Often, the SVFs
are autologous in nature and the process of obtaining
SVFs may require a procedure with a physician. On the
contrary, culture expanded stem cells involve cell growth
and cell expansion using various nutrients in a labora-
tory setting. Thus, culture expanded stem cells are usu-
ally considered to be a pharmaceutical product requiring
government regulatory clearance and approval in Korea
[4]. Due to such government regulatory issues, adipose
SVF has been more commonly used for various ortho-
pedic applications in clinical settings. Currently two
common forms of SVFs are readily available: bone
marrow and adipose tissue [5].
Although MSCs can be found in numerous human
tissues, a clinically applicable quantity of autologous
non-culture expanded MSCs can be obtained only
from bone marrow and adipose tissue [5, 6]. MSCs
contained in adipose tissue are called adipose tissue-
derived stem cells (ASCs) and are considered to be
one specific type of MSCs, and they have been shown
to differentiate into bones and cartilage [5–9]. In
2001 and 2002, Zuk et al. showed that adipose tissue
contains MSCs in SVF and that these MSCs have the
capacity to differentiate into cartilage and bone [8, 9].
The earliest clinical application of autologous adipose
SVF with one surgical procedure to treat widespread
traumatic calvarial defects was reported in 2004 by
Lendeckel et al. [10].
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In 2011, Pak had successfully used autologous adipose
SVF for cartilage and bone regeneration in human
patients without a surgical procedure [11]. Afterward,
numerous clinical studies have been published about
OA treatment with autologous adipose SVF. We con-
ducted a literature search in the PubMed, Medline, and
Embase. We used the keywords as our search terms. We
combined terms for selected indications (stromal vascu-
lar fraction, stem cell, orthopedic, and adipose). The
literature search included all studies published in English
between 2010 and 2016. The criteria for the inclusion of
studies in our review encompassed clinical studies on
autologous adipose SVF injection conducted on humans
for orthopedic applications. These studies will be
reviewed in this article and summarized in Table 1.
Autologous adipose SVF
Preparation of autologous adipose SVF
In order to obtain autologous adipose SVF, liposuction is
first performed. The resulting adipose tissue is called
lipoaspirate. The lipoaspirates are then digested with
collagenase to break down the matrix. Consequently,
MSCs are released from the matrix of the adipose tis-
sue [8, 9]. These MSCs are termed adipose tissue-
derived stem cells (ASCs). Afterward, by using the
centrifugation-and-dilution method, the ASCs are iso-
lated and collagenase is washed off. After 3 to 4
rounds of centrifugation and dilution, the bottom few
milliliters of the end-product are obtained. The end-
product is considered to be SVF [8, 9]. Autologous
adipose SVF contains a variety of cells: MSCs, peri-
cytes, vascular adventitial cells, fibroblasts, pre-
adipocytes, monocytes, macrophages, red blood cells,
fibrous tissue, and extracellular matrix (ECM) [8, 9].
Stem cells in autologous adipose SVF
The number of stem cells contained in the adipose SVF
can fluctuate widely. In adipose tissue, the numbers of
nucleated cells can range from 500,000 to 2,000,000 cells
per gram (g) of adipose tissue, and 1 to 10% of these nu-
cleated cells are considered to be ASCs [12]. The num-
ber of ASCs in 1 g of adipose tissue may vary from 5000
to 200,000 stem cells [12]. Theoretically, in 100 g of adi-
pose tissue, 0.5–20 million ASCs can be extracted in the
SVF form. One of the reasons for such variation can be
attributed to individual differences. Different patients
have different adipose tissue texture and density [13].
Some of the adipose tissue is denser than the other,
probably due to different amount of ECM.
In addition to differences in individual adipose tissue,
collagenase may also play an important role, affecting
the yield and viability of stem cells in SVF. High dosage
or prolonged exposure to collagenase may be toxic to
stem cells. Thus, an excess amount of collagenase can
decrease stem cell viability. However, insufficient
amount of collagenase may result in an inefficient and
inadequate amount of stem cell yield [14]. Thus, using
the correct amount of collagenase is very important. In
addition, the correct type of collagenase is just as im-
portant. There are numerous types of collagenase avail-
able commercially. Collagenase is produced by two
separate and distinct genes in the bacterium Clostridium
histolyticum. The colG gene codes for type I collagenase
and the colH gene codes for type II collagenase. Various
enzymes such as elastase, trypsin, and/or papain can be
added to these two types of collagenase to increase the
specificity for certain tissues [15].
Current clinical applications of autologous
adipose SVF in cartilage regeneration
Cartilage regeneration in OA
OA is a debilitating health problem common in elderly
patient populations worldwide. Painful OA lowers qual-
ity of life by limiting the normal daily activities of
patients [16, 17]. Current existing medical treatments
aim to remedy symptoms only. Commonly prescribed
treatments include non-steroidal anti-inflammatory
drugs (NSAIDs), steroids, hyaluronic acids (HAs), and
physical therapy. However, MSCs, in the form of autolo-
gous adipose SVF or culture expanded form, are an
alternative therapy that can potentially treat the under-
lying cause of OA by regenerating cartilage.
One of the major drawbacks of applying autologous
adipose SVF in orthopedic conditions is the lack of avail-
ability of randomized controlled studies. Most, if not all,
literature available with regard to the human application
of autologous adipose SVF are either in the format of
case reports or cohort studies. Due to such constraints,
despite the successful results reported by these articles,
it is not yet readily accepted as a mainstream medical
treatment.
In 2011, for the first time, Pak reported a case series of
treating patients with OA of the knees with autologous
adipose SVF and regenerating cartilage-like tissue [11].
Pak obtained autologous adipose SVF from digesting
about 100 g of adipose tissue with collagenase and going
through the centrifugation-dilution washing cycle as
described by Zuk et al. [8, 9]. This autologous adipose
SVF, with platelet rich plasma (PRP) and HA, was then
injected percutaneously into the knee joints of two
patients. After 3 months, the visual analog score (VAS)
for pain, functional rating index (FRI), and range of
motion (ROM) of the patients were assessed and shown
to be improved along with MRI evidence of cartilage
regeneration [11]. The inclusion criteria and exclusion
criteria were listed as follows: Inclusion criteria: (i)
chronic or degenerative joint disease causing significant
functional disability and/or pain; (ii) the failure of
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conservative treatments; and (iii) an unwillingness to
proceed with surgical intervention. Exclusion criteria: (i)
active inflammatory or connective tissue disease thought
to impact pain condition (i.e., lupus, rheumatoid
arthritis, and fibromyalgia); (ii) active non-corrected
endocrine disorder that might impact pain condition
(i.e., hypothyroidism and diabetes); (iii) active neurologic
disorder that might impact pain condition (i.e., periph-
eral neuropathy and multiple sclerosis); (iv) pulmonary
and cardiac disease uncontrolled with medication usage;
(v) history of active neoplasm within the past 5 years;
(vi) blood disorders documented by abnormal complete
blood count (CBC) within 3 months including severe
anemia, thrombocytopenia, leukocytosis and/or leukope-
nenia; and (vii) medical conditions precluding the injec-
tion procedures.
Subsequently in 2013, Pak et al. reported a retrospect-
ive cohort study involving 91 patients with various
orthopedic conditions [18]. Between the period of 2009
and 2010, Pak et al. treated 91 patients with OA of the
knees, OA of the hips, and osteonecrosis of the femoral
heads with percutaneous injections of autologous adi-
pose SVFs along with autologous PRPs and HAs. The
study reported the average efficacy of the regenerative
treatment to be 65% at 3 months without any serious
side effects and without any development of tumors.
Some of the side effects reported were swelling and
tendonitis [18].
In 2016, Pak et al. published a case series reporting
that addition of autologous adipose ECM along with the
SVF may also be effective when used together with
autologous PRP and HA [19]. As in other reports, Pak et
al. obtained autologous adipose SVF from digesting
100 g of adipose tissue with a collagenase. However, this
time, unlike other reports, they added autologous adi-
pose tissue-derived ECM, extracted by using an adipose
tissue homogenizer, into the mixture of autologous adi-
pose SVF, along with autologous PRP and HA. The mix-
ture was injected into the knees of three patients with
OA of the knees. Three months after treatment, all
three patients’ symptoms, measured using FRI, ROM,
and VAS pain score, improved. In addition, compari-
son of pre-treatment and post-treatment MRI data of
all three patients demonstrated cartilage-like tissue
regeneration [19].
In 2012, Koh and Choi also reported a retrospective
cohort study treating 25 OA patients with autologous
adipose SVF with autologous PRP [20]. This group ob-
tained autologous adipose SVF from digesting only 19 g
of adipose tissue extracted from the knee fat pad. Koh et
al. also used the centrifugation-dilution method
described by Zuk et al. [8, 9]. As performed by Pak et al.,
these adipose SVFs with autologous PRP was percutan-
eously injected into the knees of 25 patients with OA
after performing arthroscopic debridement and lavage.
The article states that the mean Lysholm knee scoring
scales, Tegner activity level scales, and VAS scores im-
proved significantly in the treated group compared to
the control group. No imaging studies were carried out.
No major side effects were reported [20].
In 2013, Koh et al. reported a case series involving 18
patients with OA of the knees receiving autologous adi-
pose SVF obtained from digesting only 9 g of adipose
tissue from the knee fat pad [21]. The autologous adi-
pose SVF with autologous PRP were percutaneously
injected into knees of 18 patients after arthroscopic
debridement and lavage. After a few months, the pa-
tients were evaluated with Western Ontario and
McMaster Universities osteoarthritis index (WOMAC)
scores, Lysholm knee scoring scales, and VAS scores and
MRI studies. The patients improved on all criteria,
including the cartilage whole-organ MRI scores. No
serious complications were reported [21].
In 2014, Koh et al. reported a case series involving
second-look arthroscopy results in 35 patients with knee
OA treated with autologous adipose SVF [22]. In this
report, Koh et al. incorporated arthroscopic guidance
when injecting the knees with adipose SVF. Initially, the
patients underwent arthroscopic examinations with
debridement and lavage. Afterward, autologous adipose
SVF with autologous PRP were injected under arthro-
scopic guidance. Only about 23 g of adipose tissue was
used. About 12.7 months after treatment, second-look
arthroscopy was performed. The results showed that the
mean International Knee Documentation Committee
(IKDC) and Tegner activity level scales significantly
improved, but 76% of the patients had abnormal repair
tissue observed during arthroscopy [22].
In another study reported by Koh et al. in 2014, the
clinical results and second-look arthroscopy findings
were compared between an autologous adipose SVF/
PRP injection group and a PRP-only group [23]. This
study involved 44 patients undergoing open-wedge
high tibial osteotomies (HTO). This time, autologous
adipose SVF were obtained from 120 g of adipose tis-
sue from the patients’ buttocks. Afterward, the au-
tologous adipose SVFs were injected with autologous
PRP in 23 patients under arthroscopic guidance and
the other 21 patients were injected with autologous
PRP alone under arthroscopic guidance. After
24 months of the treatment, the results showed that
the autologous adipose SVF/PRP group showed sig-
nificantly greater improvement than the PRP-only
group, as measured by VAS for pain, Knee injury
Osteoarthritis Outcome Score (KOOS) subscales for
pain and symptoms, and second-look arthroscopic
evaluation. Arthroscopic exams showed fibrocartilage
regeneration in 50% of the adipose SVF/PRP group
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versus 10% in the PRP-only group. However, the Lysholm
score was similarly improved in both groups [23].
Later in 2015, Koh et al. reported another case series
involving second-look arthroscopy results of 30 patients
with OA of the knees treated with autologous adipose
SVF obtained from 120 g of adipose tissue from the pa-
tients’ buttocks [24]. The autologous adipose SVF was
injected with PRP under arthroscopic guidance. Of the
30 patients, 16 patients underwent second look arthros-
copies about 25 months after the initial treatment. Of
the 16 patients, 10 patients (63%) had improved cartil-
age, 4 patients (25%) had maintained the cartilage, but 2
patients (12%) failed in healing cartilage defects. The
study reported that all patients showed significant im-
provement in OA outcome scores (KOOS), VAS pain
scale, and Lysholm score [24].
In another study, Kim et al. compared the efficacy of
autologous adipose SVF alone to that of autologous adi-
pose SVF with fibrin glue [25]. The fibrin glue was used
as a scaffold for stem cells to attach. This study involved
54 patients with knee OA. Autologous adipose SVF was
obtained from digesting 120 g of adipose tissue with col-
lagenase. Of the 54 patients, 37 patients were treated
with autologous adipose SVF only and the other 17
patients were injected with autologous adipose SVF with
fibrin glue. After about 28 months, the mean IKDC
score and Tegner activity level scale in both groups were
compared and had improved significantly; the improve-
ment was comparable in both groups. However, in
second-look arthroscopies, International Cartilage Repair
Society (ICRS) scores were better in the adipose SV with
fibrin glue group [25].
In 2014, Bui et al. reported a case series involving 21
patients with OA of the knees [26]. The patients were
treated with autologous adipose SVF with PRP. The adi-
pose SVF was obtained from digesting 50–100 ml of
lipoaspirates originating from the abdomen. Then, the
autologous adipose SVF with autologous PRP was
injected percutaneously into the diseased knees. After
8.5 months of treatment, all 21 patients showed im-
proved VAS pain score and the Lysholm score. There
was also a significant increase in the thickness of the
cartilage, as depicted on the MRIs [26].
In early 2015, Michalek et al. reported a multi-center
case-control study involving 1114 patients with OA of
the knees and hips from four different countries (USA,
Czech Republic, Slovakia, and Lithuania) [27]. These
patients were percutaneously injected with autologous
adipose SVF and followed for average 17 months. No
serious side effects were reported and no incidents of
cancer were reported. The clinical effects, measured on
the basis of pain, non-steroid analgesic usage, limping,
extent of joint movement, and stiffness, all improved. At
12 months after treatment, 63% of all patients reported
approximately 75% symptom improvement and 91% of
all patients reported approximately 50% of symptom im-
provement [27].
In 2016, Fodor et al., another group in the USA, re-
ported clinical improvement of 8 knee OA patients
treated with autologous adipose SVF obtained by digest-
ing 150–250 ml of lipoaspirates [28]. All patients
attained full activity with decreased knee pain. WOMAC
scores, VAS pain scale score, ROM, and timed up-and-
go (TUG) results all improved. The improvement in
WOMAC scores and VAS scores were maintained at 1
year. Comparing preoperative MRI to 3-months postop-
erative MRI showed no detectable structural differences.
No major side effects were observed [28].
Chondromalacia patellae (CMP)
CMP is a knee joint disorder defined by cartilaginous
softening of patellar bone cartilage and may cause patel-
lofemoral pain syndrome (PFPS), which is characterized
by anterior knee pain (AKP) along with malalignment of
the tibio-patello-femoral joint [29, 30]. CMP can be
diagnosed with MRI along with clinical history and
physical examination [29, 30]. Currently, only symptom-
atic treatment is available. As in OA, commonly pre-
scribed treatments include NSAIDs and physical
therapy. Thus, CMP poses a major therapeutic chal-
lenge. However, as a few recent studies have shown the
possibility of cartilage recovery using MSCs [31], the
combination of autologous adipose SVF with correction
of alignment may be a novel approach to treating CMP.
In 2013, Pak et al. reported a case series involving
three patients with CMP of the knees [32]. Pak et al.
treated these patients with autologous adipose SVF using
100 g of adipose tissue obtained from the abdomen of
the patients. The adipose SVF was injected percutan-
eously with PRP and HA. After 3 months of treatment,
the patients’ symptoms improved in terms of VAS pain
scale, FRI, and ROM. The study also showed positive re-
generation of hyaline cartilage at the patellofemoral
joints of all three patients between pre- and post-
treatment MRIs [32].
Meniscus tear
The meniscus is a fibrocartilaginous disk that functions
to transfer weight, absolve shock to the knee, and to
protect the hyaline cartilage at the knee joint [33]. With
knee injuries, the meniscus may be damaged causing it
to be torn. Such meniscus tears are initially treated con-
servatively with NSAIDs and physical therapy [34, 35]. If
conservative treatment fails, an arthroscopic meniscec-
tomy is traditionally performed. However, arthroscopic
meniscectomy, either full or partial, is associated with
early onset of OA of the knees [36]. Thus, potential
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cartilage regeneration with MSCs, or autologous adipose
SVF, may offer a major therapeutic breakthrough.
In 2014, Pak et al. reported that autologous adipose
SVF may be effective in treating meniscus tears [37].
This case report involved one patient treated with au-
tologous adipose SVF obtained from digesting approxi-
mately 40 g of packed adipose tissue with collagenase.
Afterward, the autologous adipose SVF was injected with
PRP and HA. After 3 months of treatment, the patient’s
symptoms, measured with VAS scores for pain, FRI, and
physical therapy ROM, had improved. In addition, prob-
able regeneration of the meniscus cartilage was docu-
mented by pre- and post-treatment MRIs [37].
Current clinical applications of autologous
adipose SVF in bone regeneration
Bone has an innate capability to regenerate. Upon frac-
ture, resident progenitor stem cells work to form scarless
healing [38]. However, a few clinical instances require
therapeutic interventions to facilitate bone repair and
regeneration.
Osteonecrosis of the femoral head
Osteonecrosis of the femoral head is a debilitating skel-
etal disorder of unknown etiology that usually occurs in
young males, can lead to collapse of the hip joint and
may necessitate a total hip replacement [39].
In 2011, Pak reported that autologous adipose SVF
may have the capability to regenerate bone in the lesion
of osteonecrosis of the femoral head [11]. Pak obtained
autologous adipose SVF from digesting 100 g of adipose
tissue with collagenase. This autologous adipose SVF
was then injected percutaneously with PRP and HA into
hip joints of two patients. After 3 months, VAS for pain,
FRI, and ROM of the hips were improved, and there was
MRI evidence of bone regeneration [11].
Subsequently in 2012, Pak reported the long-term ef-
fect of autologous adipose SVF on bone regeneration in
patients with osteonecrosis of the femoral head [40]. Of
the two patients involved, one patient was followed for
7 months and the other patient for 16 months. The pa-
tients’ symptom improved and the MRI showed positive
bone regeneration in both patients. Both patients clearly
showed maintenance of the regenerated bone for a rela-
tively long time period [40].
In another case report, Pak et al. treated a patient with
stage 1 osteonecrosis of femoral head with autologous
adipose SVF [41]. Pak et al. obtained adipose SVF from
digesting 100 g of adipose tissue with collagenase. The
autologous adipose SVF with PRP and HA was injected
into the femoral head under ultrasound guidance. Three
months after the injection, patient’s symptom completely
resolved and the MRI findings of necrosis resolved
completely as well. A subsequent MRI taken a few
months later showed maintenance of the regenerated
bone [41].
Bone fracture
In a case report by Saxer et al. in 2016, autologous adi-
pose SVF was used with ceramic granules within fibrin
gel to treat proximal humeral fractures in conjunction
with standard open reduction and internal fixation in
eight patients [42]. Up to 12 months after the procedure,
biopsies of the repair tissue were performed and dem-
onstrated formation of bone ossicles that were struc-
turally disconnected and morphologically distinct
from osteoconducted bone, which suggests the osteo-
genic nature of implanted SVF cells. This study
demonstrated spontaneous bone tissue and vessel for-
mation within a fracture microenvironment with au-
tologous adipose SVF [42].
Non-union fracture
Although autologous adipose SVF may be indicated for
treatment of a non-union fracture, there have not been
any reports so far.
Current clinical applications of autologous (or
allogeneic) adipose SVF in tendon/ligament
regeneration
For patients with chronic tendinopathy, conservative
medical management, including anti-inflammatory
drugs, physiotherapy, braces, and therapeutic exercises,
has produced unsatisfactory outcomes [43, 44]. Although
corticosteroid injection has been widely used for short-
term pain relief, the effectiveness of the treatment is
transient [45, 46]. In addition, by suppressing the cellular
activity of human tenocytes and collagen synthesis,
corticosteroid injections weaken the tendon, thereby
increasing the risk of rupture [46, 47]. Injection
approaches with dextrose solutions, whole blood, and
platelet-rich plasma have been tried with limited evi-
dences of success [48]. Potential regenerative MSC ther-
apy, on the other hand, is emerging as a novel treatment
for chronic tendinopathy.
Achilles tendinopathy
In 2016, de Girolamo et al. reported a result of random-
ized prospective clinical trial involving 56 patients with
Achilles tendinopathy [49]. Of the 56 patients, 28
patients were randomly assigned to a single autologous
PRP injection and the other 28 patients were assigned to
a single autologous adipose SVF injection. All patients
were assessed clinically using VAS, Victorian Institute of
Sport Assessment for Achilles tendinopathy (VISA-A),
the American Orthopaedic Foot & Ankle Society
(AOFAS) and Short Form-36 (SF-36) forms. Before the
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treatments, all patients also underwent ultrasound im-
aging studies and MRIs; these were then repeated at 4
and 6 month follow-ups. At the final follow-up, both pa-
tients group showed significant improvements in all
scores compared to baseline (p < 0.05). In the adipose
SVF injection patients, these improvements were faster
and more pronounced. After 6 months, the MRI and
ultrasound studies showed no significant difference. No
side effects were observed in either group. The study
concluded that both PRP and SVF are safe and effective
treatments for Achilles tendinopathy, although adipose
SVF may allow faster clinical results than PRP [49].
Lateral epicondylosis
Lee et al. published an article in 2015 involving 12
patients with lateral epicondylosis treated with allogeneic
adipose-derived MSCs [50]. Although the scope of this
article is limited to autologous adipose SVF, the study by
Lee et al. is significant in light of the fact that an insuffi-
cient number of human studies are available with
regards to tendon and ligament repair. The study is a
pilot study assessing the safety and efficacy of culture ex-
panded ASCs in treating human patients with lateral
epicondylosis. The ASCs were injected with fibrin glue
under ultrasound guidance into the hypoechoic tendon
lesions of chronic lateral epicondylosis. Then, patients’
VAS score, modified Mayo clinic performance index,
and longitudinal and transverse ultrasound images of the
tendon defect areas were evaluated at 6, 12, 26, and
52 weeks. Through 52 weeks of follow-up, VAS scores
progressively decreased and elbow performance scores
improved. Tendon defects, assessed by ultrasound
images, also significantly decreased throughout the
follow-up period. No significant adverse effects were
observed [50].
Discussion
Due to the current regulatory environment, culture
expanded MSCs are considered to be a pharmaceutical
product and require governmental clearance and ap-
proval. Autologous adipose SVF injection, on the other
hand, is considered to be a medical procedure, and thus
allowed in many parts of the world. Consequently,
autologous adipose SVF is slowly being tried as an al-
ternative treatment in the field of orthopedics, treat-
ing disorders involving cartilage, bone, and tendons/
ligaments. Compared to bone marrow SVF, adipose
tissue is considered to be a preferred source of MSCs
in the form of SVF due to its ease of accessibility and
the availability of a large number of stem cells per
gram of adipose tissue [12].
Although numerous studies available that show the
effectiveness of autologous adipose SVF treatment in
OA patients, the comparison of these studies show lack
of standardization. Lacking standardization may lead to
differences in results of the treatment. Most of the
standardization may be improved with availability of cul-
ture expanded stem cells [50, 51]. With differences of
procedure in processing adipose tissue, the yield of
viable stem cells may differ from one group to the other.
However, with the availability of culture expanded stem
cells, all variables that exist in the manual process may
be eliminated, providing consistent quantity and quality
of stem cells. With the standardized availability of
culture expanded stem cells, the effectiveness would
become more improved.
In addition, it should be well known that OA, CMP,
and meniscus tear are all diseases of the joint, not just
cartilage. In these joint problems, cartilage, ligaments,
tendons, muscles, and bone are all involved. For ex-
ample, CMP involves alignment of the knee. In patients
with CMP, correction of only cartilage may not dramat-
ically improve the symptoms unless the misalignment is
also corrected. As for meniscus tear is involved, improv-
ing muscles, tendon, and ligament may also be import-
ant in addition to cartilage regeneration.
It seems the amount of autologous adipose tissue used
in producing adipose SVF has no direct relationship with
the efficacy and safety observed. Some of the studies
used only 20 g of adipose tissue while others have used
more than 100 g of adipose tissue. However, Jo el al.
showed in a double-blind randomized clinical trial that
higher number of stem cells may result in improved
cartilage regeneration [51].
Although number of ASCs contained in autologous
adipose SVF should play an important role in regenera-
tive medicine, other components in the adipose SVF
may also play important roles. Autologous adipose SVF
contains various cells including ASCs and ECM [11, 12].
It is well known that ECM excretes a variety of cytokines
and growth factors [52–54]. In addition, ECM may work
as a scaffold, assisting ASCs to adhere to the lesion [55].
As Zuk et al. showed in 2001 and 2002, ASCs in the
adipose SVF have the capacity to regenerate bone, cartil-
age, muscle, and adipose tissue. Likewise, human data is
accumulating in the field of orthopedics that ASCs con-
tained in adipose SVF can be applied to treat various dis-
orders by regenerating cartilage and bone. Recently, a
study clearly showed that regeneration of a tendon in a
human patient is possible with autologous adipose SVF.
As shown by de Girolamo et al. [49], and to a certain
extent by Lee et al. [50] since this group used culture ex-
panded ASCs, adipose SVF can be used to treat tendon
injuries. These results may be used to further extrapolate
that adipose SVF and MSCs may be used in the treat-
ment of ligament injuries.
Although the successful applications of autologous
adipose SVF in humans may represent a promising,
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minimally invasive, non-surgical alternative, many issues
(challenges and limitations) need to be resolved and
clarified before the general application of this procedure
in clinics. Firstly, how ASCs in the form of SVF may
help joint diseases remains unclear: (i) it could be due to
the secretory effects of the stem cells injected [56, 57];
(ii) it could be due to direct engraftment and differenti-
ation of the stem cells that were introduced into the dis-
eased joints [58, 59]; or (iii) it could be due to the
combination of secretory effects and direct engraftment
of the stem cells. Adipose stem cells excrete a variety of
cytokines, chemokines, growth factors, and exosomes
[60, 61]. These factors have positive effects on the sur-
rounding progenitor cells. However, there are some evi-
dence that these stem cells injected may actually become
engrafted into the tissue and differentiate into tissue-
specific stem cells [62]. It is also very possible that these
two mechanisms play a role in cartilage regeneration.
Secondly, how long can ASCs or SVF (after injection)
stay in the joint before they are cleared out? To the best
of our knowledge, most of fluid is reabsorbed within few
days after the injection of SVF. However, the fate of
ASCs injected into a joint is not yet clear. It can be as-
sumed that ASCs may stay in the joint and be attached
to the lesion via scaffold. ASCs that are attached and in-
tegrated may be able to survive prolonged period of
time. However, it can be assumed that ASCs that are not
integrated into the tissue may die slowly while excreting
various trophic factors.
Thirdly, is proper control (e.g., control group only
receiving saline washes but not stem cells) needed in
order to make a fair conclusion that the effect of SVF
seen here is due to SVF injection but not the washout of
inflammatory cytokines by saline? Since it is possible
that PRP may have a regenerative potential, three are
studies comparing PRP to autologous SVF to confirm
the regenerative effects of SVF [20, 23, 49]. However, it
is necessary to have a controlled study comparing saline
control group to autologous SVF group to confirm the
real effect of SVF.
Fourthly, whether would the quality of ASCs affect the
therapeutic effect? For example, will ASCs from obese vs
non-obese patients have similar results of healing? It is
very well known that people have different texture of
adipose tissue as well as differences in adipose cell size
[63]. Thus, the lipoaspirate tissue must be different in
different individuals. Since the lipoaspirate processing
step, including the dosage of the collagenase, is usually
constant within the treating group, the end result of the
different tissue must yield difference adipose SVF.
Therefore, it is very probable that there may be some
differences in quantity and quality of ASCs in obese and
non-obese patients. Compared with ASCs from non-
obese individuals, ASCs from obese individuals have
showed increased proliferation and migration capacity
but decreased differentiation capacity [64]. Multiple
studies have documented the reduction in the osteogenic
differentiation capacity of ASCs in obese individuals
[65–67]. Therefore, there is a need for investigating
whether ASCs from obese vs non-obese patients have
similar results of healing of human orthopedic disorders.
Lastly, are all the cell types contained in SVF beneficial
for disease healing? The adipose SVF contains numerous
cells types, including red blood cells (RBCs), white blood
cells (WBCs), adipocytes, along with MSCs [8, 9]. In
addition, the adipose SVF may contain left-over collage-
nase, which can cause connective tissue damage, as it is
being used to breakdown the connective tissue in the
adipose tissue. These extra cells (RBCs and WBCs),
either intact or fragmented, may elicit other responses.
It is probable that the joint swelling after injecting the
autologous adipose SVF may be due to these extra cells
and/or collagenase contained in the SVF [18].
Conclusions
Autologous adipose SVF, containing MSCs that are
termed ASCs, has a great clinical potential to treat vari-
ous orthopedic disorders as seen in human studies.
Along with autologous adipose SVF, double-blind, ran-
domized human clinical trials are being conducted using
culture expanded MSCs with promising results. Until
culture expanded stem cells are available for various
orthopedic applications, autologous adipose SVF may be
worthwhile to try in individuals for whom medical treat-
ment has failed and for whom surgical options are not
available.
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